“The Government of India intends to disinvest its entire stake in IMPCL through strategic disinvestment with transfer of management control. The KMVNL …has expressed its willingness to disinvest along with GoI,” the Department of Investment and Public Asset Management (DIPAM) said.
The company is presently manufacturing 656 classical ayurvedic, 332 unani and 71 proprietary ayurvedic medicines for a varied spectrum of diseases.
It supplies ayurveda and unani medicines to all the states under the National Ayush Mission (NAM) and 6,000 centres of Jan Aushadhi Kendras.
“The price/rate of IMPCL products are fixed by the Government of India. Liberalized pricing policy post disinvestment combined with already laid down distribution network & payment collection mechanism may enable the company to compete with other market players more efficiently that may lead to increased sales and profitability,” the DIPAM said. As of March 31, 2022, the company had a paid-up share capital of Rs 51.98 crore. The total campus area of IMPCL is 35.81 acres in Almora, Uttarakhand. IMPCL is a profit-making organisation since its inception. The Profit Before Tax (PBT) of IMPCL was Rs 42.77 lakh during FY 2019-2020, which surged to Rs 45.41 crore for 2021-2022.
Denial of responsibility! My Droll is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
